WILMINGTON, Mass., March 18, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it will exhibit its QS-B220 explosives trace detector at booth # 802 at Air Cargo 2014. Air Cargo 2014 will take place from March 30 through April 1, 2014 at the Marriott World Center in Orlando, Florida.

Air Cargo is the premier annual trade show and conference for the AEMCA (Air & Expedited Motor Carriers Association), the AfA (Airforwarders Association), the XLA (Express Delivery & Logistics Association), and ACI-NA (Airports Council International - North America) which co-host Air Cargo as a service to the industry. The conference includes diverse educational program for attendees, outstanding business opportunities for exhibitors and excellent corporate exposure for sponsors. Each year, Air Cargo brings together a virtual "who's who" of the industry within the express delivery, air freight forwarding and expedited motor carrier industries.

"Air Cargo 2014 is an important industry conference for us as we continue to build market share in the cargo screening market. We closed on numerous contracts with new customers as a direct result of exhibiting at Air Cargo 2013. Since last year's show, our QS-B220 has been added to the Qualified Products section of the TSA Air Cargo Screening Technology List and approved by STAC in France. We expect that these approvals coupled with increased regulation of air cargo screening on a global basis such as the EU's ACC3 requirements will continue to increase opportunity for our QS-B220," commented Dr. Darryl Jones, Implant Sciences' Vice President of Sales and Marketing.

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and  the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at http://www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700

or

Investor Contact:
Laurel Moody
646-810-0608

SOURCE Implant Sciences